Ga-DOTA positron emission tomography/computed tomography (CT)] have a pivotal role in the diagnosis of neuroendocrine tumors (NETs), although their indication during follow-up still needs to be clarified.
N
euroendocrine tumors (NETs) are identified at advanced disease stages in 40% to 70% of cases and are associated with a mortality rate twofold higher than localized disease (1) (2) (3) (4) . They express somatostatin receptors in ;90% of patients (5) , which can be detected by functional imaging tests (FITs). Among these techniques, which represent a standard procedure for whole-body imaging of NETs (6) (7) (8) (9) (10) (11) (12) , 68 Ga-DOTA peptide positron emission tomography (PET)/computed tomography (CT) ( 68 Ga-DOTA-PET/CT) is more accurate than somatostatin receptor scintigraphy (SRS; Octreoscan ® ), but it is not widely available (6, 13) .
The pivotal contribution of FITs to the diagnosis of NETs is well known, both for staging and therapeutic purposes. In fact, primary and metastatic sites are identified with a sensitivity rate of 60% to 80% by SRS and of 90% to 95% by 68 Ga-DOTA-PET/CT (10) (11) (12) (13) (14) . Moreover, FITs allow the selection of patients eligible for both cold somatostatin analogs and peptide receptor radionuclide therapy (15) (16) (17) .
In contrast, the role of FITs in the follow-up of NETs is still unclear. In fact, disease status and response to treatments are usually assessed by CT or magnetic resonance imaging (MRI) according to the response evaluation criteria in solid tumors (18) . However, evidence-based studies defining the timing of these tests are lacking, and follow-up strategies are mainly based on prognostic factors and clinical experience (19) . Furthermore, after the introduction of targeted therapies (i.e., everolimus and sunitinib) and peptide receptor radionuclide therapy, the need for further tools, besides conventional imaging tests, is being debated (20) . The guidelines proposed by the European Neuroendocrine Tumors Society (ENETS) suggest to also adopt SRS or 68 Ga-DOTA-PET/CT after diagnosis, but for which kind of patients and in which time frame (12 or 24 months) is not clearly specified (21) (22) (23) .
The aim of this study was to define, in the follow-up of sporadic stage IV enteropancreatic NETs, the clinical usefulness of FITs, trying to identify the patients who might benefit from these exams, and to suggest appropriate timing to repeat them according to tumor features. Furthermore, the diagnostic yield of FITs in terms of detection of new metastases was assessed.
Subjects and Methods

Patient selection
We completed a multicenter retrospective analysis of patients responding to the following inclusion criteria ( Fig. 1 ): histological diagnosis of sporadic pancreatic (pNETs) or small intestine NETs (siNETs), presence of distant metastases (since diagnosis or developed during follow-up), somatostatin receptor expression described at a first SRS or 68 Ga-DOTA-PET/CT between January 1995 and December 2013, and a follow-up time of $2 years, with at least two FITs and two CTs per case. The exclusion criteria were no uptake at FITs, the presence of genetic syndromes (e.g., type I multiple endocrine neoplasia, von Hippel-Lindau syndrome), tumor primary site other than the pancreas or small bowel, a follow-up time of ,2 years, and/or less than two functional and morphological diagnostic examinations.
The institutional ethical committees approved this retrospective study; the need for written informed consent was waived.
Histology and imaging tests were assessed by pathologists, radiologists, and nuclear medicine specialists with a longstanding experience in NETs at every center. Patient management, including the use of FITs, was based on the institutional standard care of practice until 2004, and thereafter on the ENETS practice guidelines (21) (22) (23) (24) .
Patients received a CT every 6 months (unless clinical conditions and tumor behavior required shorter intervals) and a FIT every 12 months.
At the Rome, Berlin, Milan, and Graz sites, both SRS (1995 to 2007) and 68 Ga-DOTA-PET/CT (2008 to 2016) were performed, whereas at the Marburg site only SRS was adopted.
Imaging procedures
All CT images were obtained with a multiple-detector scanner, using intravenous iodine contrast and studying at least the chest and abdomen (25) . Arterial phase images were acquired 30 to 35 seconds after the injection, and portal venous phase was obtained with a delay of 70 to 80 seconds. Multiplanar reformations on coronal and sagittal planes were reconstructed on a workstation.
FITs were performed according to institutional standard procedure. Planar images for SRS were acquired, using a 256 3 256-pixel matrix, at 24 h and 48 h after the injection of [ 111 In] pentetreotide. Abdominal 360°single-photon emission CT was carried out in all patients at the end of the 24-hour planar study (26) .
The labeling procedure of DOTA peptides (TOC/NOC/ TATE) with 68 Ga was performed according to Zhernosekov et al. (27) . PET/CT images were carried out using a dedicated hybrid PET/CT tomography (Gemini TF 16; Philips Medical Systems) 1 hour after intravenous injection of standard dose of 68 Ga-DOTA peptide, in conformity with the European Association of Nuclear Medicine guidelines (28, 29) . A low-dose CT was acquired immediately before the PET scan and used for attenuation correction (120 kVp, 30 mAs).
Information on CT, SRS, and 68 Ga-DOTA-(TOC/NOC/ TATE)-PET/CT was retrieved from written reports or registers of interdisciplinary meetings (NET tumor boards), where imaging was reviewed by experts.
Data analysis
The clinical usefulness of FITs was defined as the occurrence, during follow-up, of useful changes in patient management (i.e., indication to biopsy, new therapies or dose escalation, surgery or further radiological examinations) due only to FITs. Data were retrieved from patients' charts or reports of NET tumor boards by two investigators per site.
Inappropriate changes were recorded as well and were defined as modifications of management not determining a real benefit for patients. In detail, they were represented by indication to further biopsy, diagnostic tests, or therapeutic decisions due to incorrect detection of disease progression by CT and/or FITs.
The time frame in which the clinical changes were observed was also evaluated to assess a possible correlation to tumor features.
For what concerns the diagnostic yield of FITs, it was defined as the number of new metastases (not present at the first assessment of stage IV disease), detected only by FITs and missed by CT. The gold standard adopted was the result of all imaging tests, the surgical and pathological findings obtained during the observation of each patient.
For this analysis, follow-up time was divided into 12-month observation units, each including at least one CT and one FIT to be compared in terms of detection of new lesions. In every observation unit, we considered the CT with the closest date to FIT. We excluded units with MRI and without chest CT or contrast enhancement.
To limit the bias due to comparison of SRS and 68 Ga-DOTA-PET/CT, clinical changes and new metastases were also detailed according to the type of FIT (Supplemental Tables 1 and 2) .
No distinction between the different 68 Ga-tracers (DOTA-NOC, DOTA-TOC, or DOTA-TATE) was evaluated.
Statistical analysis
Statistical analysis was performed using a dedicated software program (Medcalc 15.6.1, http://www.medcalc.be).
The distribution of continuous variables was reported as the median and range. A comparison between the subgroups was carried out using Fisher's exact test or the x 2 test for noncontinuous variables, and the Mann-Whitney U test or the analysis of variance test for continuous variables.
A P value was considered statistically significant when ,0.05.
Logistic regression was adopted to investigate a possible correlation of tumor features with the occurrence of clinical changes due to FITs, or with their timing (12 or 24 months). Results were expressed in terms of odds ratio (OR) and 95% confidence interval (CI). The multivariate model was constructed by the "enter method," including all variables that had shown significance at the univariate analysis.
Accuracy rates in diagnosing new metastases of CT plus FIT vs CT alone were compared by the McNemar test.
Results
Patient demographics
One hundred forty-three metastatic enteropancreatic NETs were included in the current study (Fig. 1) , 69.2% (99/143) presenting as stage IV since the first diagnosis. Features at study entry are described in Table 1 .
Functional syndromes included carcinoid syndrome in 42 cases, Zollinger-Ellison syndrome in six, insulinoma in one, and glucagonoma in one.
The first-line treatment was surgery in 93 patients (with curative intent in 58), somatostatin analogs in 44, everolimus in one, and chemotherapy in five.
Median follow-up was 36 months (range, 24-84), with a total number of 424 observation units (251 with SRS, 173 with 68 Ga-DOTA-PET/CT). Forty-seven patients received only SRS as functional imaging.
Clinical usefulness of FITs
Patient management was modified 168 times in 127 cases, but eight changes (six by CT, two by FITs) were inappropriate. SRS was responsible for 55 out of 168 (32.7%) clinical changes vs 62 out of 168 (36.9%) due to 68 Ga-DOTA-PET/CT.
FITs were clinically useful during the follow-up of 73.4% (105/143) patients, with a significant correlation to G grading (30, 31) . In detail, OR of G2 vs G1 tumors was 2.40 (95% CI, 1.09 to 5.27; P = 0.03) ( Table 2) .
For what concerns a possible influence of tumor features on timing of clinical changes due to FITs, the occurrence of changes in a 12-month (vs 24-month) time frame was associated at multivariate analysis to primary site and presence of metastases since tumor first diagnosis. In fact, when comparing pancreatic to small bowel cases, OR was 2.42 (95% CI, 1.09 to 5.37; P = 0.03); instead, OR of stage IV since NETs' diagnosis vs developing metastases only in follow-up was 2.87 (95% CI, 1.19 to 6.90; P = 0.02).
FITs had an impact on clinical decisions more than once in 16 patients, mostly after a first benefit observed in a 12-month time frame (OR, 4.42; 95% CI, 1.20 to 16.20; P = 0.02).
Detection of new metastases
One hundred seventy-four new metastases occurred in 92 patients during follow-up (Supplemental Table 2 ), 75 Ga-DOTA-PET/CT (diagnosed during diagnostic laparoscopy).
FITs detected 75.8% (132/174) of new lesions, including 29.3% (51/174) that had been missed by CT (diagnostic yield of FITs; P , 0.01) ( Table 3 ). The accuracy rate in diagnosing new lesions was 73.9% for CT alone, but reached 98.4% when associated to FITs (P , 0.01). In detail, impact of functional imaging in follow-up was significant both for intra-abdominal and extra-abdominal sites (P , 0.01), reaching the highest yield with 68 Ga-DOTA-PET/CT for extra-abdominal metastases (64.3%, P , 0.01).
Discussion
The present study shows that FITs have a relevant role during the follow-up of metastatic enteropancreatic NETs, as they can change patient management in 73.4% of cases, mostly in terms of prescription of new treatments. This benefit is related to an increase in the detection of new metastases, as the association of FITs to CT allows the diagnosis of one-third more new intraabdominal and extra-abdominal lesions that CT alone would miss. The impact of FITs on clinical decisions is higher for G2 tumors, and they should be repeated yearly for pNETs or for disease being stage IV since diagnosis. Several studies have already tried to investigate the role of FITs for NETs, emphasizing their ability to complete disease staging. However, they mostly focused on diagnosis (12, 32) , and only a minority analyzed the contribution of FITs to patient management, reporting their clinical usefulness as ranging from 11.7% to 40.9% (32) (33) (34) (35) (36) (37) . Our results suggest a higher impact of these tests on patient management (73.4%), probably because we considered a longer period of observation (24 to 84 vs 6 to 12 months in previous studies).
The association of FITs to conventional imaging would be controversial for the subsequent economical impact (38) , but follow-up programs tailored according to tumor features might improve cost-effectiveness. Our results indeed show FITs to determine a major benefit for metastatic G2 vs G1 tumors (OR, 2.40; P = 0.03), probably due to a higher proliferative index and thus a more aggressive potential behavior. Furthermore, in our 68 Ga-DOTA-PET/CT, without focusing on follow-up (12, 13, (32) (33) (34) 39) . As our hypothesis was that FITs offer complementary information to CT and cannot replace conventional imaging (34, 39) , we have investigated how diagnostic accuracy might be improved associating these two types of tests in follow-up of NETs. Furthermore, because response evaluation criteria in solid tumors (18) can be applied to CT but not to FITs, for this outcome we have considered as disease progression only the appearance of new metastases and not any increase in lesion size. Previous publications mostly focused on different inclusion criteria and mixed diagnosis to following observation, thus reporting a wide range of yield of FITs (15% to 50%) (12, 13, (32) (33) (34) 39) . Our results have supported the significant contribution that FITs might offer in disease restaging, identifying nearly 30% new metastases that CT alone had missed, localized not only in extra-abdominal but also intra-abdominal organs (P , 0.01).
The well-known superiority of 68 Ga-DOTA-PET/CT vs SRS in terms of accuracy (6, 13) has been also confirmed, as diagnostic yield of these two techniques was 37.7% and 18.4%, respectively, reaching the highest value for new extra-abdominal lesions (64.3% and 42.1%, respectively).
The present study has some limitations. In detail, as the clinical usefulness of FITs is higher in our series than in previously published data, a selection bias due to the inclusion of more aggressive cases might be suspected. However, FITs are usually adopted in metastatic patients' follow-up at the participating sites. Furthermore, the collection of only 143 cases from five NETs referral centers is not due to this bias, but to the strict inclusion criteria adopted: histologically proven pNETs and siNETs, metastatic, with a minimum 2 year-follow up, facing only CT as conventional radiological tests. This relatively small population also did not allow a subanalysis according to different 68 Ga-DOTA-PET/CT tracers. Another limitation is due to the lack of a central reading for imaging in this multicenter study, which was not feasible due to the retrospective design and long enrollment period. However, the protocols used to perform the diagnostic tests represented standard procedures and were homogeneous between the different sites. Moreover, all the involved centers were experienced in NETs' management, following the ENETS guidelines (21) (22) (23) (24) and discussing every decision in interdisciplinary meetings. The choice to exclude patients followed up with MRI was taken to further limit the bias to compare this test with CT, but subsequently our results should be considered only for cases restaged by this latter imaging.
The inclusion of both SRS and 68 Ga-DOTA-PET/CT as FITs might also represent a limitation, especially if both are adopted for the same patient. Although the superiority of 68 Ga-DOTA-PET/CT is clear, we decided to also consider SRS in this study because it still represents in many centers the only available test to investigate somatostatin receptor expression. Additionally, SRS has shown in our series, when added to CT, a significant impact both on patient management and on disease restaging.
Conclusions
In metastatic enteropancreatic NETS' follow-up, the use of FITs in addition to CT has a significant impact on clinical management (especially for G2 patients), and it increases the detection rate of new lesions. These tests should be repeated more frequently in pNETs and in cases with the presence of metastases since diagnosis. Prospective studies are needed to define follow-up programs tailored to tumor features, and to assess their potential benefit in terms of progression-free and overall survival.
